(Q30458424)

21 June 2017

title

BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies (English)

1 reference

21 June 2017

1 reference

Richard D Hall

1

1 reference

21 June 2017

Ragini R Kudchadkar

series ordinal

2

1 reference

21 June 2017

publication date

1 July 2014

1 reference

21 June 2017

1 reference

21 June 2017

volume

21

1 reference

21 June 2017

issue

3

1 reference

21 June 2017

page(s)

221-230

1 reference

Mutations of the BRAF gene in human cancer

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Targeting the BRAF V600E mutation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF mutations in hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Mammalian MAP kinase signalling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Mechanisms of regulating the Raf kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Tumor adaptation and resistance to RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF as a potential therapeutic target in melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF point mutations in primary melanoma show different prevalences by subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

A phase II trial of sorafenib in metastatic melanoma with tissue correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Mutation Affecting the 12th Amino Acid of the c-Ha- ras Oncogene Product Occurs Infrequently in Human Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Lessons from hereditary colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Feasibility of screening for Lynch syndrome among patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

CpG island methylator phenotype in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF mutation in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF V600E inhibition in anaplastic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Uncommon V599E BRAF mutations in Japanese patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Genetic predictors of MEK dependence in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

BRAF inhibition in refractory hairy-cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100307

10.1177/107327481402100307

21 January 2018

Identifiers

DOI

0 references

1 reference